PremiumThe FlyCelularity receives notice regarding non-payment of Nasdaq fees Celularity welcomes CMS action on Medicare LCD for skin substitutes products Celularity announces publication highlighting potential of CYNK-001 PremiumThe FlyMASS Coalition welcomes order freezing skin substitute LCDs Celularity Faces Challenges as Agreement Expires Celularity announces resolution of Nasdaq listing compliance matter PremiumThe FlyCelularity resolves Nasdaq listing compliance issue Celularity raises FY24 revenue view to $54M-$60M from $50M-$56M Celularity files amended compliance plan with Nasdaq Hearings Panel 
